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A 45-year-old female who presented with loss of consciousness and a cold sweat was found to have a 
pancreatic tumor and multiple liver metastases.  Laboratory studies showed marked hypoglycemia and 
inappropriately elevated serum insulin,  C-peptide,  and serum tumor markers.  Fine needle aspiration 
revealed Grade 3 small-cell type primary pancreatic neuroendocrine carcinoma.  Consequently,  the 
diagnosis of malignant insulinoma was made.  Transarterial embolization (TAE) for hepatic metasta-
ses resulted in the reduction of tumor volume and prompt resolution of hypoglycemic attacks,  whereas 
diazoxide and systemic chemotherapy had been ineﬀective for controlling blood glucose levels,  and 
octreotide was unavailable due to the allergic eﬀect.  This case report highlights the potential useful-
ness of TAE for malignant insulinomas in the management of hypoglycemia.
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nsulinomas,  arising from β cells in the islets of 
Langerhans,  induce hypoglycemia by secreting 
excessive insulin.  The majority of cases present with 
a solitary pancreatic tumor,  the surgical resection of 
which is curative.  On the other hand,  malignant 
insulinoma,  which presents with multiple hepatic 
metastases or recurrence after surgical resection,  is 
refractory to surgery and/or systemic chemotherapy.  
The metastasis rate of insulinoma is reported to be 
5.4ｵ [1].  In the management of malignant insuli-
noma,  controlling blood glucose levels is particularly 
vital,  because hypoglycemia adversely aﬀects quality 
of life and is sometimes life-threatening.  We herein 
report a case of malignant insulinoma with hepatic 
metastases,  in which hepatic transarterial emboliza-
tion (TAE) was eﬀective for volume reduction of the 
metastatic tumors and subsequent prompt resolution of 
hypoglycemia.  Strategies for the prevention of hypo-
glycemia in insulinoma patients are discussed.
Case Report
　 A 45-year-old female presented with 2-month 
duration of left hypochondrial pain,  occasional loss of 
consciousness,  and cold sweats.  She was emergently 
admitted given her loss of consciousness and a blood 
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glucose level of 20mg/dl.  After the admission,  she 
frequently developed hypoglycemic attacks even during 
meals or while receiving an intravenous dextrose solu-
tion.  She was transferred to our hospital for further 
treatment.  The patient had no family history of 
neuroendocrine tumors or other endocrine tumors.  
Physical examination revealed no abnormality.  
Laboratory examination showed hypoglycemia (54mg/
dL) and inappropriately high serum immunoreactive 
insulin (IRI) (67.5µU/mL) and C-peptide (6.3ng/mL) 
levels.  Tumor markers including CA19-9 (53.7U/
mL),  NSE (169.9ng/mL),  DUPAN-2 (235U/mL),  
and SPAN-1 (36.1U/mL) were elevated.  Complete 
blood count and chemistries were otherwise normal.
　 Abdominal computed tomography (CT) scans 
showed a solitary pancreatic tumor having clear 
enhancement with contrast media.  Portal inﬁltration 
by the tumor and enlarged lymph nodes around the 
pancreas head were also noted.  In addition,  multiple 
tumors were detected in the liver (Fig.  1).  Fine-
needle aspiration biopsy performed for the hepatic and 
pancreatic tumors revealed atypical cells with oval-
shaped eccentric nuclei,  deeply stained chromatin,  and 
eosinophilic cytoplasm.  Immunohistochemical staining 
was positive for chromogranin A,  synaptophysin and 
CD56.  The Ki-67 index was 27ｵ.  Thus,  a diagnosis 
of Grade 3 small-cell type primary pancreatic neu-
roendocrine carcinoma was made (Fig.  2).
　 Although high-calorie infusion was initiated,  hypo-
glycemic episodes occurred and administration of 
glucose was required orally or intravenously to treat 
each episode.  Diazoxide was orally administered,  but 
it was not eﬀective to prevent hypoglycemia.  Sub-
cutaneous infusion of octreotide was also tried,  but 
had to be stopped due to allergic reactions.  To pre-
vent the hypoglycemic episodes,  TAE using Embozene® 
was performed on the right and left hepatic lobes on 
days 12 and 22,  respectively.  Glucose levels were 
normalized after the next day of the ﬁrst TAE,  and 
no hypoglycemia was observed during days 13 to 61 
(Fig.  3).  The levels of CA19-9,  NSE,  IRI and 
C-peptide decreased (Fig.  4),  and contrast CT scans 
performed 4 weeks after the TAE (Fig.  5) showed a 
clear decrease of hepatic metastases.  On day 41,  
systemic chemotherapy with etoposide and cisplatin 
was initiated.  Despite 3 courses of the chemotherapy,  
hepatic metastases increased and hypoglycemic attacks 
recurred.  The patient deteriorated due to a catheter-
associated fungal infection and died on day 157.
Discussion
　 Diazoxide,  a non-diuretic benzothiazine derivative,  
has aﬃnity for the sulfonylurea receptor and blocks 
opening of ATP-sensitive potassium channels [2].  
Based on this chemical property,  diazoxide inhibits 
insulin secretion from pancreatic β cells [3].  Therefore,  
diazoxide is eﬀective for controlling blood glucose 
levels in patients with malignant insulinoma [4].  
Octreotide,  a somatostatin derivative,  is another drug 
that is able to prevent hypoglycemia in insulinoma 
patients.  Octreotide inhibits insulin secretion by 
competitively blocking cyclic AMP production.  
However,  70-80ｵ of insulinomas do not express 
somatostatin receptors [5],  and thus somatostatin 
antagonists are ineﬀective in such cases.  Moreover,  
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Fig. 1　 Contrast-enhanced CT scans on admission.  Arterial phase (A) and portal phase (B) of the CT scans showed a 2.7-cm tumor 
with diminished contrast eﬀect and an ill-deﬁned border in the pancreatic body (white arrows),  in addition to dilation of the main pancreatic 
duct in the caudal portion.  Multiple tumors were also detected in the liver,  showing ring-shaped enhancement in the early phase and 
washout in the late phase (black arrows).
octreotide may aggravate hypoglycemia in patients 
with insulinomas,  because it might also inhibit gluca-
gon secretion.
　 Physicians from only 2 institutions have reported 
four cases in which TAE has been performed for 
hepatic metastases of malignant insulinomas [6,  7];  
to the best of our knowledge,  our case is the 5th.  As 
the initial therapy,  the 4 cases were administered 
interferon,  diazoxide,  or combination therapy with 
adrimycin and streptozocin,  but these treatments were 
abandoned because of strong side eﬀects or lack of 
therapeutic eﬀect.  But a survival time of 14 to 31 
months or more was achieved by performing TAE 
after these initial therapies.  In each of the three cases 
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Fig. 2　 Histopathological ﬁndings.  In hematoxylin-eosin staining (A),  atypical cells exhibiting oval-shaped eccentric nuclei with deeply 
stained chromatin and eosinophilic cytoplasm were observed.  Immunostaining for synaptophysin (B) and chromogranin A (C) were positive.  
The Ki-67 index (D) was 27%.  The tumor was thus diagnosed as G3 small-cell neuroendocrine carcinoma according to the WHO classiﬁ-
cation.
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Fig. 3　 Clinical course.  Glucose levels were normalized after 
TAE.
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Fig. 4　 Clinical course.  Serum tumor markers tended to decrease 
after TAE.
reported in detail,  TAE was performed 2-3 times 
during the observation period and no exacerbation of 
symptoms or increase of serum glucose or insulin 
levels or tumor size was observed.  In the present 
case,  TAE was performed because of the ineﬀective-
ness of octreotide and diazoxide,  which were adminis-
tered to improve the hypoglycemic attack; after TAE,  
temporary improvement of serum glucose and insulin 
levels,  abdominal symptoms and tumor size was 
observed.  On the other hand,  the survival time was 
short,  about 4 months,  probably because the prolif-
erative potency was signiﬁcantly high,  with a Ki-67 
index of 27ｵ.  The Ki-67 indexes of the 4 other cases 
are unknown; hence,  it is not clear whether the 
malignancy grades were the same as the present case.
　 Hepatic metastases of neuroendocrine tumor (NET) 
in 80-90ｵ of the cases are already too diﬃcult to 
excise at the time of diagnosis.  The standards of local 
treatment for hepatic metastases are TAE and tran-
sarterial chemoembolization (TACE) [8],  although at 
present there are not many case reports of TAE or 
TACE for hepatic metastases of NET that have ended 
well [9].  In cases where the number of unresectable 
liver metastases is limited,  sometimes tumor ablation 
is useful.
　 In the current case,  we performed TAE for 
hepatic metastases to decrease the tumor bulk and to 
prevent hypoglycemic attacks,  since diazoxide was 
ineﬀective and octreotide was not available due to the 
allergic reaction.  Reduction of symptoms by TAE 
treatment have been reported in 64-93ｵ of neuroen-
docrine carcinoma patients with hepatic metastasis for 
a period varying between 1 and 18 months [8].  
Radiological response (i.e.,  partial response and com-
plete response) was reportedly 37-74ｵ,  the 5-year 
survival rate for TAE is 40-54ｵ.  Kress et al.  
reported that prognosis was improved when the num-
ber of liver metastases is small and suﬃcient lipiodol 
accumulation was obtained [10].  In the presented 
patient,  the blood glucose levels promptly improved 
after the initial TAE,  and hypoglycemic attacks dis-
appeared.  Furthermore,  CT scans revealed signiﬁ-
cant decreases of the tumor volume.  Decreases in 
levels of tumor markers (e.g.,  CA19-9 and NSE) in 
addition to IRI and C-peptide,  were also noted.
　 Systemic chemotherapies have also been used for 
pancreatic neuroendocrine carcinomas.  Prior reports 
suggest comparatively favorable eﬀects of combination 
therapy with etoposide and cisplatin,  or with irinote-
can and cisplatin [11,  12].  However,  no randomized 
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Fig. 5　 Contrast CT scans before TAE (A) after TAE (B).  Reduction of the tumor volume and necrosis was observed in most of the 
multiple liver metastatic nodules.
controlled trial of chemotherapies for this disease has 
been conducted,  and no survival beneﬁt has been 
demonstrated.  Moreover,  generally it takes more 
than 2-3 weeks to obtain considerable reduction of 
tumor volume by systemic chemotherapy; conse-
quently,  immediate improvement of glucose levels is 
unlikely to occur by chemotherapy alone.  In the pres-
ent patient,  we administered 3 courses of etoposide 
and cisplatin [13],  but the size of tumors increased 
and the patient continued to suﬀer from multiple epi-
sodes of hypoglycemia.
　 In conclusion,  prompt resolution of hypoglycemia 
was achieved by TAE in a malignant insulinoma 
patient with hepatic metastases.  This case indicates 
that TAE is useful in the management of malignant 
insulinomas for prevention of hypoglycemic attacks,  
particularly for cases in which drugs such as diazoxide 
and octreotide are ineﬀective or unavailable.
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